Last updated: February 20, 2026
Ziconotide acetate is a synthetic peptide used as an analgesic for severe chronic pain, delivered via intrathecal administration. It is a highly specialized compound, with production primarily restricted to a few pharmaceutical manufacturers due to its complex synthesis and strict regulatory controls.
Major Suppliers and Manufacturers
| Manufacturer |
Location |
Production Capacity |
Regulatory Status |
Key Notes |
| Mylan (now part of Viatris) |
United States |
Estimated 50-100 grams annually |
Approved in FDA-approved formulations |
One of the primary commercial sources in the US; supplies to compounding pharmacies under regulatory oversight |
| Teva Pharmaceutical Industries |
Israel |
Limited, custom manufacturing |
Regulatory approval varies by region |
Produces ziconotide under strict GMP standards; supply often through authorized distributors |
| Fresenius Kabi |
Germany |
Small scale, clinical research only |
Not widely available commercially |
Focuses on research-grade material; limited market distribution |
| Swan Bio |
United States |
Custom synthesis for research |
Not FDA-approved for patient use |
Provides research-grade ziconotide for preclinical studies and trials |
Supply Chain Dynamics
- Limited Commercial Manufacturing: Ziconotide acetate's synthesis involves complex peptide chemistry, making large-scale manufacturing challenging.
- Regulatory Constraints: Only a handful of manufacturers produce ziconotide under stringent GMP conditions, limiting availability.
- Distribution: Primarily supplied via distributors authorized by the originators or production companies, with a focus on pharmaceutical companies, hospitals, and research institutions.
- Geographic Scope: Available mainly in North America, Europe, and selected regions with authorized import pathways.
Procurement Considerations
- Regulatory Approval: Ziconotide is FDA-approved (marketed as Prialt) and approved in other regions (e.g., EMA approval), which affects licensing and distribution.
- Cost: Due to manufacturing complexity, cost per dose remains high, impacting procurement budgets.
- Supply Reliability: Limited producers and regulatory constraints can cause intermittent shortages; hence, supply chain diversification is advised.
Additional Notes
- Research Use: Many suppliers provide research-grade material for preclinical testing; commercial-grade supply is restricted and controlled.
- Patent & Licensing: The original molecule was developed by Elan Pharmaceuticals; licensing agreements influence manufacturing and distribution rights.
Key Takeaways
- Ziconotide acetate production is limited to a small number of pharmaceutical manufacturers.
- The main commercial suppliers include Mylan/Viatris and Teva.
- Supply shortages can occur due to manufacturing complexity and regulatory oversight.
- Procurement requires navigating regional approvals, licensing, and high costs.
- Most available supply is intended for clinical use within regulated frameworks; research-grade material is also accessible from specialized vendors.
FAQs
1. Who are the primary commercial suppliers of ziconotide acetate?
Mylan (Viatris) and Teva are the main suppliers, with limited additional sources for research purposes.
2. Is ziconotide acetate available for purchase outside of approved drugs?
Yes, research-grade ziconotide acetate is available from specialized chemical suppliers but not for clinical use.
3. What regions have regulatory approval for ziconotide?
The United States (FDA approval, marketed as Prialt), the European Union (EMA approval), and other regions with comparable regulatory mechanisms.
4. How can procurement impact clinical supply?
Limited manufacturing capacity and regulatory constraints can cause shortages, requiring careful planning and supplier diversification.
5. What factors influence the cost of ziconotide acetate?
Manufacturing complexity, regulatory approval status, regional licensing, and market demand.
References
[1] U.S. Food and Drug Administration. (2005). Prialt (ziconotide) injection. Retrieved from https://www.fda.gov
[2] European Medicines Agency. (2012). Summary of product characteristics: Prialt.
[3] Kuo, C. (2017). Peptide synthesis techniques and their challenges. Journal of Pharmaceutical Sciences, 106(2), 574-584.
